Get started
ReutersReuters

Molecular Partners Reports Q3 2025 Financial Results And Clinical Progress, With Dll3-Targeting Radio-Darpin Mp0712 Phase 1 Launch Expected In 2025

RefinitivLess than 1 min read
MOLN

Molecular Partners AG MOLN:

  • MOLECULAR PARTNERS REPORTS Q3 2025 FINANCIAL RESULTS AND CLINICAL PROGRESS, WITH DLL3-TARGETING RADIO-DARPIN MP0712 PHASE 1 LAUNCH EXPECTED IN 2025

EuropeReutersSwiss stocks
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Login or create a forever free account to read this news

More news from Reuters